The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the [gamma][delta] T-Cell Receptor.

Original title: “Government Owned Invention Available for License: Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor”

The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.

Original title: “Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for development of papilloma- infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.

Original title: “Government Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)”

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

Original title: “Braveheart, Attovia join next wave of biotech IPOs”

Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.

Original title: “Pfizer scraps Seagen-developed ADC for solid tumors”

After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total.

Original title: “Biotech IPOs surge in H1 of 2026, shattering records and doubling last year’s total”

The choices that change a career often look like extra work at the time. Executive coach Angela Justice examines why the projects, questions, relationships and conversations people almost dismiss can become the ones they later recognize as turning points.

Original title: “The biggest career decisions don’t feel like career decisions”

AI tools can help job seekers write resumes and mass apply to open positions, but those aren’t the only, or best, ways to use them. A career coach shares how she advises clients to make the most of AI during the application and interview process.

Original title: “Standing out, not blending in: how AI tools can drive impact during job searches”

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

Original title: “Judge orders Apple Tree partner to forfeit oversight of venture fund”

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

Original title: “Draig bags another $65M to speed testing of brain drugs”

The agency’s finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like Compass Pathways, whose psilocybin-based therapy for treatment-resistant depression could win approval as early as this year.

Original title: “Final psychedelics guidance suggests FDA is 'receptive' to helping companies succeed”

In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.

Original title: “Bonus: Q2 2026 Job Market Update”